三黄连合剂通过NLRP3/ASC/Caspase-1通路对哮喘患儿气道炎症的机制研究  

Mechanism of Sanhuanglian Mixture on Airway Inflammation in Children With Asthma Through NLRP3/ASC/Caspase-1 Pathway

作　　者：张晓[1] 梁剑[1] 王文佳[1] 游楚明[1] ZHANG Xiao;LIANG Jian;WANG Wenjia;YOU Chuming(Department of Pediatrics,Guangdong Second Provincial General Hospital,Guangzhou Guangdong 510317,China)

机构地区：[1]广东省第二人民医院儿科,广东广州510317

出　　处：《中国卫生标准管理》2024年第11期140-145,共6页China Health Standard Management

基　　金：2021年广东省中医药局科研立项项目(20211018)。

摘　　要：目的探讨三黄连合剂通过NOD样受体蛋白3(NOD-like receptor protein domain associated protein 3,NLRP3)/凋亡相关颗粒样蛋白(apoptosis-associated speck-like protein containing a CARD,ASC)/半胱氨酸天冬氨酸蛋白酶1(cysteine aspartic acid specific protease-1,Caspase-1)通路对哮喘患儿气道炎症的作用及机制。方法选取2021年1月—2023年10月就诊的90例哮喘患儿,采用数字表法随机分为观察组与对照组,各45例。观察2组哮喘患儿不良反应、1 s用力呼气容积(forced expiratory volume in the first second,FEV_(1)%)、最大呼气流量(peak expiratory flow,PEF)、用力肺活量(forced vital capacity,FVC)、白细胞介素-1β(interleukin-1β,IL-1β)及TNF-α(tumor necrosis factor-α,TNF-α)表达水平差异。结果观察组不良反应发生率为6.66%,对照组为11.11%,差异无统计学意义(P>0.05)。观察组总有效率为95.56%,高于对照组的80.00%(P<0.05)。治疗后FEV_(1)%、PEF、FVC、哮喘控制测试表(asthma control test,ACT)评分高于对照组(P<0.05)。治疗后观察组血清IL-1β、IL-6、IL-8、IL-17、IL-18水平低于对照组(P<0.05)。治疗后观察组患儿血清NLRP3、ASC、Caspase-1、IL-1β蛋白表达水平低于对照组(P<0.05)。结论三黄连合剂治疗能减轻哮喘患儿气道炎症反应,降低炎症因子水平,改善肺功能,减轻病情,提高疗效,其可能通过NLRP3/ASC/Caspase-1通路发挥作用。Objective To explore the effect and mechanism of Sanhuanglian mixture on airway inflammation in children with asthma through the NOD-like receptor protein domain associated protein 3/Apoptosis-associated speck-like protein containing a CARD/Cysteine aspartic acid specific protease-1 pathway.Methods From January 2021 to October 2023,a total of 90 children with asthma were randomly divided into observation group and a control group,with 45 casea in each group.The adverse reactions,forced expiratory volume in the first second(FEV_(1)%),peak expiratory flow(PEF),forced vital capacity(FVC),interleukin-1β(IL-1β)and tumor necrosis factor-α(TNF-α)of the two groups of children with asthma were observed.Results The incidence of adverse reactions in the observation group was 6.66%,while in the control group was 11.11%,with no statistically significant difference(P>0.05).The total effective rate of the observation group was 95.56%,which was higher than the 80.00%of the control group(P<0.05).After treatment,FEV_(1)%,PEF,FVC,Asthma control test,the ACT score were higher than that of the control group(P<0.05).Post treatment observation group serum IL-1βwas lower than those of the control group(P<0.05).After treatment,the serum NLRP3,ASC,Caspase-1,and IL-1βwere lower than those of the control group(P<0.05).Conclusion The treatment of Sanhuanglian mixture can alleviate airway inflammation in children with asthma,reduce levels of inflammatory factors,improve lung function,alleviate the condition,and enhance therapeutic efficacy.It may play a role through the NLRP3/ASC/Caspase-1 pathway.

关 键 词：三黄连合剂 NLRP3/ASC/Caspase-1通路 不良反应 哮喘 炎症因子 气道炎症 

分 类 号：R725[医药卫生—儿科]